Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis

Fig. 2

NMA Network of treatment comparisons for efficacy outcomes contained within the identified clinical studies. The major classes of agents analyzed in the selected trials for NMA are indicated along the perimeter of the figure: NNRTIs in orange, INSTIs in green, PIs in purple and connectors in blue. Black lines connecting each of the treatments of interest (red dots) represent a publication or clinical trial containing those 2 agents of interest. A connector is a treatment not of interest that is compared with at least two different treatments of interest that are included in the analysis to provide additional data. ATV, atazanavir; ATV/r, ritonavir-boosted atazanavir; BIC, bictegravir; DTG, dolutegravir; DRV/r, ritonavir-boosted darunavir; EFV, efavirenz; EVG/c, cobicistat-boosted elvitegravir; FPV/r, ritonavir-boosted fosamprenavir; INSTIs, Integrase strand inhibitors; LPV/r, lopinavir-boosted ritonavir; NFV, nelfinavir; NMA, network meta-analysis; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; RAL, raltegravir; RPV, rilpivirine; SQV/r, ritonavir-boosted saquinavir; VS, virologic suppression

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us